Generate Biomedicines (NASDAQ:GENB) Shares Gap Down – What’s Next?

Generate Biomedicines Inc (NASDAQ:GENB) shares gapped down before the market opened on Monday . The stock had previously closed at $16.00, but opened at $15.25. Generate Biomedicines shares last traded at $13.7710, with a volume of 347,864 shares.

Analyst Ratings Changes

A number of research firms recently issued reports on GENB. Guggenheim began coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target on the stock. Cantor Fitzgerald began coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating for the company. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Finally, Piper Sandler started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price target for the company. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Down 19.2%

The business has a 50-day moving average of $12.95.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.